Some companies do it for the headlines. Lumen Bioscience builds revolutions in algae. The Seattle-based biotech just secured a $30M Series C extension led by WestRiver Group, pushing its total raise to $186.8M. That’s not pocket change, it’s the kind of capital that turns moonshots into manufacturable realities. When Brian Finrow and Jim Roberts, MD, PhD founded Lumen in 2017, they weren’t trying to ride the biotech wave, they were trying to reengineer it. Their weapon of choice? Spirulina. Not the smoothie-bar supplement, but a genetically engineered organism turning oral biologic drugs into a real business model.
Finrow, a Harvard Law grad and former Adaptive Biotechnologies exec, teamed up with Roberts, the Howard Hughes and Fred Hutch legend, to tackle one of biotech’s biggest choke points: cost. Antibody drugs save lives, but they bleed money. Lumen’s bet was simple, what if we could grow drugs instead of manufacturing them? Fast-forward to now, and that question’s worth $186.8M in validation.
With 2 cGMP facilities humming in Seattle, including a second site at 4501 11th Ave NW, the company’s vertical integration isn’t just a buzzword. From hit-to-lead protein engineering to GMP manufacturing and clinical development, everything happens under one roof. The result: speed, control, and a price-per-dose that makes Big Pharma’s spreadsheets sweat.
Their lead candidate, LMN-201, just cleared Phase 2 for recurrent C. difficile infection, a disease that costs U.S. hospitals ~$8B annually. The RePreve trial didn’t just hit; it proved that edible algae could carry therapeutic antibodies where pills and powders couldn’t. Add in collaborations with NIH, NIAID, the Gates Foundation, and DoD funding for countermeasure work, and you see a company that doesn’t wait for validation, it earns it, repeatedly.
The Series C extension isn’t about survival; it’s about scaling. Lumen is ramping GMP capacity, deepening its clinical pipeline, and adding leadership muscle with execs like Nhi Khuong, PhD, Kole Krieger, and CFO Don Schlosser. Board members Jeff Raikes, the former Gates Foundation CEO, and Erik Anderson from WestRiver Group know exactly what kind of acceleration this funding buys.
Every biotech claims to change the world. Lumen just engineered a platform that can afford to. The spirulina play isn’t just clever, it’s structural. It cuts through decades of manufacturing bloat, opens up global access, and redefines how we think about biologics. In a market obsessed with speed, Lumen isn’t racing, they’re rewriting how the race is run.
